The solution for acyclovir-resistant HSV infection:

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections lead to lifelong persistence of the virus, with frequent and sometimes painful recurrences, and carry the risk of serious complications in immune-compromised patients. Pritelivir is a highly potent inhibitor of HSV replication. It belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). In contrast to currently used nucleoside analogues, Pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is being developed for the treatment of acyclovir-resistant and dual-resistant (resistant to acyclovir and intolerant or resistant to foscarnet) infections in immune-compromised patients. It has received the US FDA Breakthrough Therapy Designation and a phase 3 trial is starting based on promising phase 2 data.


Early Access


AiCuris supports expanded access requests for Pritelivir for the treatment of eligible patients and collaborates with myTomorrows to facilitate early access to Pritelivir for acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

-> Read more ...